Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) EBT (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed EBT for 3 consecutive years, with -$74.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 18.72% to -$74.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$203.8 million through Dec 2025, up 15.64% year-over-year, with the annual reading at -$203.8 million for FY2025, 15.64% up from the prior year.
  • EBT hit -$74.9 million in Q4 2025 for NewAmsterdam Pharma, down from -$72.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$16.6 million in Q3 2024 to a low of -$93.8 million in Q1 2024.
  • Historically, EBT has averaged -$51.9 million across 3 years, with a median of -$44.6 million in 2023.
  • Biggest five-year swings in EBT: soared 64.68% in 2024 and later plummeted 332.51% in 2025.
  • Year by year, EBT stood at -$49.5 million in 2023, then crashed by 86.34% to -$92.2 million in 2024, then rose by 18.72% to -$74.9 million in 2025.
  • Business Quant data shows EBT for NAMS at -$74.9 million in Q4 2025, -$72.0 million in Q3 2025, and -$17.4 million in Q2 2025.